ViroPharma

ViroPharma

ViroPharma (/ˌvaɪroʊˈfɑːrmə/) is a pharmaceutical company that specializes in the development and commercialization of antiviral medications. The company was founded in 1994 and is headquartered in Exton, Pennsylvania, USA.

Etymology

The name "ViroPharma" is a combination of the words "virus" and "pharmaceuticals", reflecting the company's focus on the development of antiviral drugs.

History

ViroPharma was founded in 1994 by a group of scientists and entrepreneurs with a shared vision to create new antiviral medications. The company initially focused on the development of treatments for Hepatitis C, but has since expanded its research and development efforts to include a wide range of viral diseases.

In 2013, ViroPharma was acquired by Shire Pharmaceuticals, a global biotechnology company based in Ireland. The acquisition allowed Shire to expand its portfolio of rare disease treatments and strengthen its position in the global pharmaceutical market.

Products

ViroPharma's flagship product is Cinryze, a C1 esterase inhibitor that is used to treat hereditary angioedema, a rare and potentially life-threatening condition that causes swelling in various parts of the body. The company also developed Vancocin, an antibiotic used to treat infections caused by Clostridium difficile and Staphylococcus aureus.

Related Terms

• Pharmaceutical Industry
• Antiviral Drug
• Hepatitis C
• Shire Pharmaceuticals
• Cinryze
• Vancocin
• Hereditary Angioedema
• Clostridium Difficile
• Staphylococcus Aureus

External links

• Medical encyclopedia article on ViroPharma
• Wikipedia's article - ViroPharma

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski